The estimated Net Worth of Mark Coleman is at least $4.6 million dollars as of 28 May 2024. Mark Coleman owns over 10,497 units of Axsome Therapeutics Inc stock worth over $1,329,038 and over the last 9 years he sold AXSM stock worth over $3,013,485. In addition, he makes $257,810 as Independent Director at Axsome Therapeutics Inc.
Sign up
Mark Coleman AXSM stock SEC Form 4 insiders trading
Mark has made over 10 trades of the Axsome Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 10,497 units of AXSM stock worth $789,059 on 28 May 2024.
The largest trade he's ever made was selling 29,588 units of Axsome Therapeutics Inc stock on 15 September 2023 worth over $2,224,426. On average, Mark trades about 3,200 units every 68 days since 2015. As of 28 May 2024 he still owns at least 14,600 units of Axsome Therapeutics Inc stock.
You can see the complete history of Mark Coleman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Coleman biography
Dr. Mark Coleman M.D. serves as Independent Director of the Company. Dr. Coleman served as a consultant to us. Dr. Coleman is currently the President of National Spine and Pain Centers, or NSPC, the nation’s largest interventional pain management group. His clinical duties include serving as the Medical Director of the Pikesville, Maryland branch. Dr. Coleman served as Director of Novel Therapies at NSPC from 2009 to 2011. NSPC routinely evaluates emerging treatments for pain through the conduct of clinical trials. Dr. Coleman is a Diplomat of the American Board of Anesthesiology in Anesthesiology and Pain Management. Dr. Coleman holds an M.D. from Johns Hopkins University School of Medicine and received his undergraduate degree from Wesleyan University. Dr. Coleman's medical expertise and business experience make him qualified to serve on our board.
What is the salary of Mark Coleman?
As the Independent Director of Axsome Therapeutics Inc, the total compensation of Mark Coleman at Axsome Therapeutics Inc is $257,810. There are 8 executives at Axsome Therapeutics Inc getting paid more, with Herriot Tabuteau having the highest compensation of $4,715,750.
How old is Mark Coleman?
Mark Coleman is 52, he's been the Independent Director of Axsome Therapeutics Inc since 2014. There are 2 older and 11 younger executives at Axsome Therapeutics Inc. The oldest executive at Axsome Therapeutics Inc is David Marek, 55, who is the Chief Commercial Officer.
What's Mark Coleman's mailing address?
Mark's mailing address filed with the SEC is C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK, NY, 10007.
Insiders trading at Axsome Therapeutics Inc
Over the last 9 years, insiders at Axsome Therapeutics Inc have traded over $3,013,485 worth of Axsome Therapeutics Inc stock and bought 82,512 units worth $1,366,003 . The most active insiders traders include Roger Jeffs, Susan Mahony et Mark Coleman. On average, Axsome Therapeutics Inc executives and independent directors trade stock every 114 days with the average trade being worth of $1,405,685. The most recent stock trade was executed by Mark E Saad on 11 September 2024, trading 11,016 units of AXSM stock currently worth $40,429.
What does Axsome Therapeutics Inc do?
axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.
What does Axsome Therapeutics Inc's logo look like?
Complete history of Mark Coleman stock trades at Axsome Therapeutics Inc
Axsome Therapeutics Inc executives and stock owners
Axsome Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Herriot Tabuteau,
Chairman of the Board, President, Chief Executive Officer, Founder -
David Marek,
Chief Commercial Officer -
Nick Pizzie,
Chief Financial Officer -
Dr. Herriot Tabuteau M.D.,
Founder, Chairman, CEO & Pres -
Mark L. Jacobson,
COO & Sec. -
Nick Pizzie CPA, M.B.A.,
Chief Financial Officer -
Roger Jeffs,
Lead Independent Director -
Mark Saad,
Independent Director -
Mark Coleman,
Independent Director -
Amanda Jones,
Senior Vice President - Clinical Research -
Cedric O'Gorman,
Senior Vice President - Clinical Development and Medical Affairs -
Mark Jacobson,
Chief Operating Officer -
Joseph Debrah-Afful CPA, M.B.A.,
Director of Fin. -
Kevin Laliberte Pharm.D.,
Exec. VP of Product Strategy -
Lori Englebert M.B.A.,
Sr. VP of Commercial & Bus. Devel. -
Dr. Amanda Jones Pharm.D.,
Sr. VP of Clinical Devel. -
Constance Ames,
Vice President, Finance -
Myrtle S Potter,
Director -
Randall Kaye,
Chief Medical Officer -
Hunter R. Murdock,
General Counsel -
John Golubieski,
Chief Financial Officer -
Susan Mahony,